Cerebrolysin: what the research shows

  • By Reed Calder
  • Last reviewed Nov 12, 2026
  • 41 studies and official documents checked

In short

Cerebrolysin is a mixture of small peptides and amino acids made by breaking down pig brain protein, and it is given by injection or drip. It is a prescription drug for stroke, head injury and dementia in dozens of countries, and it is not approved in the United States. A 2023 Cochrane review of stroke trials found it probably doesn’t reduce deaths and may raise non-fatal serious side effects. Many of the trials with the best results were run or funded by its maker. The one published analysis of a bought sample found no pieces of the brain growth factors it is often said to contain.

EvidenceCellAnimalHuman

Cerebrolysin is sold online as a “peptide” and talked about as a memory and recovery drug. This page covers what it is, what the stroke, head-injury and dementia trials found and who paid for them, what is known about its contents, the safety signals, and where it stands legally.

Names and forms you’ll see

The names on Cerebrolysin products
Name What it is Studied in people?
Cerebrolysin The brand name of an injection made by EVER Neuro Pharma of Austria: a mixture of peptides and free amino acids from pig brain (maker’s prescribing information) Yes, mostly as a drip
“Cerebrolysin peptide” A search phrase and a sales label. It is a mixture of peptides and amino acids, not one peptide (Florek et al., 2025) Same as Cerebrolysin
Cerebrolysin-like products Other brain-extract preparations, such as Cortexin, which a Cochrane review pooled with Cerebrolysin (Ziganshina et al., 2023). Their peptide mixtures differ from Cerebrolysin’s in one 2024 test (Seidl and Aigner, 2024) Some
“Cerebrolysin nasal spray” or “tablet” The prescribing information we read lists a solution for injection only (maker’s prescribing information) Not as sold; see the claims below

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The FDA registry lists it as a structurally diverse substance, because it is a mixture and not one molecule.

Cerebrolysin CAS numbers
Form CAS number Registry record
Cerebrolysin 12656-61-0 FDA GSRS

What Cerebrolysin is

Cerebrolysin is made by breaking down pig brain proteins with enzymes and purifying the result. It dates to 1949 in Innsbruck, Austria, and a 2025 review counts 44 countries where it is used, mostly in Europe and Asia (Florek et al., 2025). The prescribing information lists indications for cerebrovascular disorders, especially Alzheimer-type dementia, vascular dementia, stroke and head injury. It lists three contraindications: hypersensitivity, epilepsy and severe kidney impairment (maker’s prescribing information).

The maker describes about 25% low-molecular-weight peptides and 75% free amino acids (Florek et al., 2025). In 2015, researchers analysed a Cerebrolysin sample obtained over the internet and identified 638 unique peptides, mostly from tubulin, actin and myelin basic protein. They found no fragments of the brain growth factors BDNF, GDNF, NGF or CNTF, and suggested the reported effects may come from unknown peptides (Gevaert et al., 2015). A 2023 analysis also traced peptides to myelin basic protein and tubulin (Yang et al., 2023). That is one bought sample, not the maker’s own quality data.

In rats after a stroke, Cerebrolysin increased the growth of new brain cells and improved recovery in weeks 3 to 5. Blocking a signalling pathway called sonic hedgehog reversed the benefit (Zhang et al., 2013). In mice, it has also been given as a nasal spray (Sadigh-Eteghad et al., 2018). That is animal work, not proof of what it does in people. Read the lab literature with care: our retraction check found 10 retracted papers that tested Cerebrolysin in animals or cells, eight of them since 2024, and one expression of concern. None is cited here, and they are listed below.

What has been studied

Stroke

  • The independent review. A 2023 Cochrane review pooled 7 trials with 1,773 people who started treatment within 48 hours of an ischaemic stroke. Deaths were about the same: risk ratio 0.96 (95% CI 0.65 to 1.41, moderate certainty). Total serious adverse events were similar (risk ratio 1.16, 95% CI 0.81 to 1.66), but non-fatal serious events were more common with Cerebrolysin (risk ratio 2.39, 95% CI 1.10 to 5.23, in 3 trials with 1,335 people), and more so in the two trials that gave 30 mL for 10 days, 300 mL in all (2.87, 95% CI 1.24 to 6.69). The reviewers rated most trials as unclear risk of bias, and four of the seven had a high risk from missing outcome data. The maker supported three of the multicentre trials (Ziganshina et al., 2023).
  • The large neutral trial. The CASTA trial gave 1,070 people in Asia either 30 mL of Cerebrolysin or a saline placebo, by drip once a day for 10 days, on top of 100 mg of aspirin a day, starting within 12 hours of a stroke, and followed them for 90 days. The main combined measure of three recovery scales showed no significant difference. In a later look at the most severely affected, 90-day deaths were 10.5% with Cerebrolysin and 20.2% with placebo, which the authors called a trend (Heiss et al., 2012).
  • Early rehabilitation. The first CARS trial gave 30 mL a day for 21 days, starting 24 to 72 hours after a stroke, alongside rehabilitation, and found better arm and hand function at day 90 (Mann-Whitney effect size 0.71, 95% CI 0.63 to 0.79). Its authors called it exploratory and small, and asked for a larger trial (Muresanu et al., 2016). Pooled with the identical second trial (442 people), the effect was 0.62, and the number needed to treat for a meaningful early gain on the NIH stroke scale was 7.1 (95% CI 4 to 22) (Guekht et al., 2017).
  • Pooled safety. A 2021 meta-analysis of 12 randomized trials (2,202 people) found no significant difference from placebo on safety outcomes, and the lowest rate of serious events was at the highest dose, 50 mL (risk ratio 0.6) (Strilciuc et al., 2021). A 2025 meta-analysis of 14 randomized trials (2,884 people) found a 1.39-point larger improvement on the stroke scale, but independence (a score of 0 to 2 on the modified Rankin scale) was not significantly higher (risk ratio 1.31, 95% CI 0.90 to 1.91), and serious events (1.08) and deaths (0.86) were not significantly different (Patel et al., 2025).
  • The maker-linked meta-analysis. Nine early-recovery trials (1,879 people) favoured Cerebrolysin on the stroke scale at about day 30, with a number needed to treat of 7.7. The paper says the maker helped identify further sources (Bornstein et al., 2018).
  • Real-world registry. C-REGS2 was an open-label registry-based comparison, not a randomized trial, in 16 countries. Of 1,769 people analysed, 1,021 got Cerebrolysin plus usual care and 748 got usual care. Disability at day 90 was better with Cerebrolysin (effect size 0.62, 95% CI 0.59 to 0.64). The maker funded it (Vosko et al., 2025). An earlier registry of 1,823 people was terminated in 2021 because it could not match 1,000 people per group (NCT02541227).
  • After clot-busting or clot removal. In an open-label trial of 341 people having the clot-busting drug alteplase, 126 of whom also got 30 mL of Cerebrolysin a day for 14 days, symptomatic bleeding into the brain was less common with Cerebrolysin (odds ratio 0.25, 95% CI 0.07 to 0.85), with no difference in disability at 90 days (Khasanova et al., 2023). In 50 people given 30 mL by drip within 8 hours of onset and daily to day 21 after clot removal, with a second course at days 69 to 90, 68% were independent at 3 months, against 44% of 50 matched earlier patients. There was no placebo and the controls were historical (Staszewski et al., 2025).
  • Other stroke types. In 50 people with bleeding around the brain from a ruptured aneurysm, given 30 mL a day for 14 days, a double-blind pilot found no difference in recovery at six months (odds ratio 1.49, 95% CI 0.43 to 5.17) (Woo et al., 2020). In 132 people with speech loss after stroke, language scores rose 14.8 points more with Cerebrolysin plus speech therapy (95% CI 9.5 to 20.1). It was double-blind, at two Romanian centres, and several authors disclose ties to the maker (Homberg et al., 2025).

Head injury

  • CAPTAIN trials. In the first trial, 46 people with moderate to severe head injury were treated (50 mL a day for 10 days, then two more courses of 10 mL a day for 10 days), and the main combined measure just missed statistical significance in the intention-to-treat analysis but reached it in the per-protocol analysis (Poon et al., 2020). The second enrolled 142 people on the same schedule and found a small-to-medium effect at day 90 (effect size 0.59, 95% CI 0.52 to 0.66) (Muresanu et al., 2020). Pooled, 185 people showed an effect of 0.60 at day 90 (95% CI 0.52 to 0.68) (Vester et al., 2021). The first trial’s registry entry lists the maker as sponsor (NCT01606111). We couldn’t read the funding statements of the other two.

Dementia

  • Vascular dementia, Cochrane. Six trials with 597 people showed better thinking scores (standardised difference 0.36, 95% CI 0.13 to 0.58) and more people rated improved overall (risk ratio 2.69, 95% CI 1.82 to 3.98), but the reviewers graded the evidence very low quality. They called the evidence base weak and said any benefit may be too small to matter. Where funding was reported, all three studies were supported by industry (Cui et al., 2019).
  • The largest vascular dementia trial. In 242 people given 20 mL a day in two courses, the thinking score improved by 10.6 points with Cerebrolysin and 4.4 with placebo over 24 weeks (Guekht et al., 2011). The registry lists the maker as sponsor and records 3 serious adverse events on Cerebrolysin and none on placebo (NCT00947531).
  • Alzheimer’s, pooled. A meta-analysis of 6 placebo-controlled trials of 30 mL a day found better thinking scores at 4 weeks (standardised difference −0.40, 95% CI −0.66 to −0.13) but not clearly at 6 months (−0.37, 95% CI −0.90 to 0.16), and a better global rating at both times (Gauthier et al., 2015).
  • Against donepezil. In 197 people given 10 mL of Cerebrolysin, 10 mg of donepezil or both, there were no significant differences between groups in thinking, daily function or behaviour at week 28. The global rating favoured Cerebrolysin and the combination (Alvarez et al., 2011). The registry lists the maker as sponsor (NCT00911807).

Mood, psychosis and healthy people

  • Psychiatry. A 2025 scoping review of three databases found 6 reports: 2 full papers (both on psychosis), one letter and three conference abstracts (Florek et al., 2025). In one of the papers, 109 people with schizophrenia on risperidone, adding 30 mL of Cerebrolysin a day for 4 weeks did not change psychotic symptoms, though memory and thinking scores were better (Xiao et al., 2012).
  • Healthy volunteers. A 1998 study of 48 healthy men given 10, 30 or 50 mL, or placebo, for 10 days found changes in brain-wave patterns. Word recall tended to be worse on placebo in the first 4 hours, and not in the Cerebrolysin groups. The highest dose, 50 mL, caused mild signs of overdose and a small drop in blood pressure (Funke et al., 1998). A 2000 report of a single oral dose of 30 mL in healthy older people described more brain alpha activity and fewer memory errors than at baseline. The abstract gives no group size or placebo group (Alvarez et al., 2000).

EvidenceCellAnimalHuman

Who paid for the main trials

A trial paid for by the maker can still be well run. The reason to check is that the independent review and several of the positive trials point in different directions.

Main Cerebrolysin trials and their funding
Study Size and design Result Who paid or ran it
CASTA (Heiss et al., 2012) 1,070 stroke patients, double-blind Main measure neutral Registry lists the maker as sponsor (NCT00868283)
CARS 1 and 2 pooled (Guekht et al., 2017) 442, double-blind, with rehabilitation Better arm and hand function at day 90 CARS 1 funded by the maker, with an author from its clinical research department (Muresanu et al., 2016)
C-REGS2 (Vosko et al., 2025) 1,769 analysed, open-label registry comparison Better disability scores at day 90 Funded by the maker (Vosko et al., 2025)
Vascular dementia (Guekht et al., 2011) 242, double-blind Thinking score up 10.6 vs 4.4 points Registry lists the maker as sponsor (NCT00947531)
Donepezil comparison (Alvarez et al., 2011) 197, double-blind, three groups No significant differences in thinking, function or behaviour Registry lists the maker as sponsor (NCT00911807)
Ruptured aneurysm pilot (Woo et al., 2020) 50, double-blind No difference at six months Hospital-run (NCT01787123)
CEREHETIS (Khasanova et al., 2023) 341, open-label Fewer symptomatic bleeds, no 90-day difference Authors declare no conflict (Khasanova et al., 2023)

The usual claims, checked

Common Cerebrolysin claims vs the studies
Claim Verdict What the studies found
It contains BDNF, NGF, GDNF and CNTF Contradicted In the one independent analysis, of a sample obtained online, no fragments of any of the four were found among 638 peptides (Gevaert et al., 2015). The sample may not match the maker’s product
It regrows or rebuilds brain cells Untested In rats after stroke it increased new-cell growth (Zhang et al., 2013). The human trials measured recovery scores, not cell growth
It is clinically proven for stroke Mixed The maker says so (maker’s page). The Cochrane review found it probably doesn’t reduce deaths (Ziganshina et al., 2023), and the 90-day independence result in a 2025 meta-analysis was not significant (Patel et al., 2025)
It is safe, with no serious side effects Mixed Pooled safety analyses found no significant difference from placebo (Strilciuc et al., 2021), but Cochrane found more non-fatal serious events (Ziganshina et al., 2023), and a life-threatening allergic reaction has been reported (Trimmel et al., 2024)
It treats Alzheimer’s and dementia Mixed Vascular dementia evidence was graded very low quality and called weak (Cui et al., 2019). In Alzheimer’s it did not differ significantly from donepezil on thinking scores (Alvarez et al., 2011)
It boosts memory in healthy people Untested One 1998 study of 48 men found brain-wave changes and a trend in word recall on placebo, not a memory boost (Funke et al., 1998). A 2000 oral-dose report compared with baseline only (Alvarez et al., 2000). We found no larger controlled trial in healthy adults
It works as a nasal spray, tablet or by mouth Untested The label lists an injection (maker’s prescribing information). The nasal studies we found were in mice (Sadigh-Eteghad et al., 2018), and the one human oral report was a single dose in healthy older people (Alvarez et al., 2000)
It is approved in over 40 countries Mixed A 2025 review counts 44 countries where it is used (Florek et al., 2025). It is not registered with the FDA, according to the maker (maker’s notice to U.S. visitors)
It is the same as Semax Contradicted No. Semax is a lab-made peptide based on a fragment of a stress hormone; Cerebrolysin is a mixture from pig brain (Gevaert et al., 2015)
Any brain-extract product is equivalent Contradicted The maker says a biological product can’t be copied exactly (maker’s FAQ). A 2024 test found similar products differed in composition (Seidl and Aigner, 2024)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

Side effects and safety

  • Contraindications. Hypersensitivity, epilepsy and severe kidney impairment (maker’s prescribing information).
  • Common effects. The maker lists dizziness, headache, sweating and nausea, and calls them rare and mild (maker’s FAQ).
  • Serious events in the stroke trials. Cochrane found more non-fatal serious events with Cerebrolysin, while later pooled analyses did not (Ziganshina et al., 2023; Patel et al., 2025). The three serious events in the vascular dementia trial all fell on the Cerebrolysin side (NCT00947531).
  • Allergic reaction. A 2024 report describes life-threatening anaphylaxis in an 85-year-old after an intravenous dose, and notes that few cases have been published (Trimmel et al., 2024).
  • Blood pressure. In healthy volunteers, the highest dose (50 mL) lowered blood pressure slightly and caused mild signs of overdose (Funke et al., 1998).
  • Animal-derived product. It is made from pig brain, and the maker says it can’t be copied exactly (maker’s FAQ). A bought vial’s contents can’t be checked from the label (Gevaert et al., 2015).
  • Setting. The trials gave it by injection or drip under medical care. A review notes that the need for a drip limits its use in psychiatry (Florek et al., 2025).

Legal and approval status

  • Not approved in the United States. The maker’s own site tells U.S. visitors it is not registered with the FDA and is not approved for sale or distribution in the United States (maker’s notice). Drugs@FDA lists no Cerebrolysin product (openFDA search, no match).
  • Not on the FDA’s compounding lists. It has no entry on the FDA’s safety-risk page (FDA, 2026) or in its May 2026 compounding categories (FDA list, May 2026). Absence from those lists isn’t approval.
  • A prosecution that names it. In 2020 a Kentucky compounding pharmacy pleaded guilty to distributing unapproved new drugs, among them Cerebrolysin, and was sentenced in 2021 to three years’ probation and forfeited $1,788,906.82, its 2019 sales of these products (Justice Department, 2020; Justice Department, 2021).
  • Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
  • Approved elsewhere. The maker’s label is the Austrian one and says details vary by country (maker’s prescribing information). Cochrane describes wide use in Russia, Eastern Europe, China and other Asian and post-Soviet countries (Ziganshina et al., 2023).
  • Sport. The World Anti-Doping Agency’s 2026 list does not name Cerebrolysin (WADA, 2026). That is not a statement that it is allowed; check with your anti-doping body.
  • “Research use only” products aren’t approved for use in people, and the maker says its product is prescription-only (maker’s prescribing information).

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and the label:

  • Whose product? The trial results belong to the maker’s injection. The only analysis of a bought sample is one sample (Gevaert et al., 2015).
  • Which route? The trials used injection or drip. A nasal spray or tablet has no matching human trial that we found (Alvarez et al., 2000).
  • Growth-factor claims. A page saying it “contains BDNF” should explain the 2015 analysis that found none (Gevaert et al., 2015).
  • Trial numbers. A page quoting a stroke result should say which trial, whether it had a placebo, who paid, and whether deaths changed (Ziganshina et al., 2023).

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite. For other compounds in this group, see brain and sleep compounds.

Trials under way

Eight cerebrolysin trials we could verify are open or about to open: see the list, with sponsor, phase, size and registry links.

What’s still unknown

  • Large placebo-controlled stroke trials run independently of the maker, with follow-up past 90 days.
  • Why Cochrane found more non-fatal serious events while later pooled analyses did not.
  • Which parts of the mixture, if any, do the work, how much of the lab evidence for its mechanism survives the retractions, and how much a vial’s contents vary from batch to batch or maker to maker.
  • The funding and full disclosures for several head-injury and dementia trials.
  • Whether any non-injected form works in patients.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Cerebrolysin. We recheck every month. Last checked Nov 12, 2026.

Flagged studies that mention Cerebrolysin

Retracted, withdrawn and flagged studies
Study What it was about Status
Sharma et al., 2023 Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles. Retracted (2026) · notice
Sharma et al., 2018 Co-Administration of TiO2 Nanowired Mesenchymal Stem Cells with Cerebrolysin Potentiates Neprilysin Level and Reduces Brain Pathology in Alzheimer's Disease. Retracted (2025) · notice
Ozkizilcik et al., 2018 Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease. Retracted (2026) · notice
Rockenstein et al., 2015 Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies. Retracted (2025) · notice
Barakat et al., 2014 Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade. Retracted (2024) · notice
Ahmed et al., 2014 Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model? Retracted (2018) · notice
Salem et al., 2014 Potential of bone marrow mesenchymal stem cells in management of Alzheimer's disease in female rats. Retracted (2018) · notice
Rockenstein et al., 2014 Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure. Retracted (2025) · notice
Rockenstein et al., 2011 Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice. Retracted (2026) · notice
Ubhi et al., 2009 Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Expression of concern (2026) · notice
Doppler et al., 2008 Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome. Retracted (2026) · notice

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Funke et al., 1998 J Neural Transm Suppl No retraction or concern
Alvarez et al., 2000 J Neural Transm Suppl No retraction or concern
Guekht et al., 2011 J Stroke Cerebrovasc Dis No retraction or concern
Alvarez et al., 2011 Curr Alzheimer Res No retraction or concern
Heiss et al., 2012 Stroke No retraction or concern
Xiao et al., 2012 Aust N Z J Psychiatry No retraction or concern
Zhang et al., 2013 Stroke No retraction or concern
Gauthier et al., 2015 Dement Geriatr Cogn Disord No retraction or concern
Gevaert et al., 2015 Drug Test Anal No retraction or concern
Muresanu et al., 2016 Stroke No retraction or concern
Guekht et al., 2017 Neurol Sci No retraction or concern
Bornstein et al., 2018 Neurol Sci No retraction or concern
Sadigh-Eteghad et al., 2018 Neuropeptides No retraction or concern
Poon et al., 2020 Neurol Sci No retraction or concern
Cui et al., 2019 Cochrane Database Syst Rev No retraction or concern
Muresanu et al., 2020 Neurol Sci No retraction or concern
Woo et al., 2020 BMC Neurol No retraction or concern
Vester et al., 2021 Neurol Sci No retraction or concern
Strilciuc et al., 2021 Pharmaceuticals (Basel) No retraction or concern
Khasanova and Kalinin, 2023 BMC Neurol No retraction or concern
Yang et al., 2023 J Chromatogr B Analyt Technol Biomed Life Sci No retraction or concern
Ziganshina et al., 2023 Cochrane Database Syst Rev No retraction or concern
Seidl and Aigner, 2024 J Med Life No retraction or concern
Trimmel et al., 2024 Case Rep Neurol Med No retraction or concern
Homberg et al., 2025 Stroke No retraction or concern
Staszewski et al., 2025 Transl Stroke Res No retraction or concern
Florek et al., 2025 Biomedicines No retraction or concern
Vosko et al., 2025 Int J Stroke No retraction or concern
Patel et al., 2025 Cureus No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is Cerebrolysin?

A prescription mixture of small peptides and free amino acids made from pig brain protein, given by injection or drip for stroke, head injury and dementia in many countries. It is not approved in the United States (maker’s prescribing information; maker’s notice).

Is Cerebrolysin a peptide?

It is a mixture. One analysis of a sample found 638 different peptides, and the maker describes free amino acids as most of the content (Gevaert et al., 2015; Florek et al., 2025).

What does Cerebrolysin do to your brain?

In rats after stroke it increased growth of new brain cells through a signalling pathway (Zhang et al., 2013). In people, trials measured recovery scores rather than cell growth.

Does Cerebrolysin work?

It depends on the question. Cochrane found little to no difference in deaths after stroke (Ziganshina et al., 2023), while several maker-funded trials found better recovery scores (Guekht et al., 2017).

Does Cerebrolysin help stroke recovery?

Results are mixed. The large CASTA trial was neutral on its main measure (Heiss et al., 2012), early-rehabilitation trials favoured it (Guekht et al., 2017), and a 2025 pooled analysis found a small score gain without a clear gain in independence (Patel et al., 2025).

Does Cerebrolysin help dementia or Alzheimer’s?

The evidence in vascular dementia was graded very low quality (Cui et al., 2019). In Alzheimer’s, a trial against donepezil found no significant difference in thinking scores (Alvarez et al., 2011).

Does Cerebrolysin help traumatic brain injury?

Two small trials and their pooled analysis, 185 people, found a small-to-medium effect at day 90 (Vester et al., 2021). There is no large independent trial that we found.

Does Cerebrolysin contain BDNF?

It is often said to. The one independent analysis found no fragments of BDNF, GDNF, NGF or CNTF in a sample obtained online (Gevaert et al., 2015).

What are the side effects of Cerebrolysin?

The maker lists dizziness, headache, sweating and nausea (maker’s FAQ). Serious allergic reaction has been reported (Trimmel et al., 2024).

Is Cerebrolysin safe?

Pooled analyses of stroke trials found no significant difference in safety outcomes from placebo (Strilciuc et al., 2021), but Cochrane found more non-fatal serious events (Ziganshina et al., 2023). Epilepsy and severe kidney impairment are contraindications (maker’s prescribing information).

Is Cerebrolysin FDA approved, and why not?

No. The maker says it isn’t registered with the FDA, and Drugs@FDA lists no product (maker’s notice; openFDA search, no match). We found no FDA statement giving a reason.

Where can I buy Cerebrolysin, and is it legal in the US?

There is no U.S.-approved product, and a compounding pharmacy was prosecuted in 2020 for distributing it as an unapproved drug (Justice Department, 2020). We don’t name or link sellers. Our guide to what to look for covers the routes people use.

Is Semax the same as Cerebrolysin?

No. Semax is a lab-made peptide; Cerebrolysin is a mixture from pig brain. No trial compared them.

Can you take Cerebrolysin as a nasal spray or tablet?

The label lists an injection (maker’s prescribing information). Nasal use was studied in mice (Sadigh-Eteghad et al., 2018).

What is the Cerebrolysin dosage?

Trials gave 10 to 50 mL a day by drip, most often 30 mL a day for 10 to 21 days, and some repeated the course. A 2025 review, citing the leaflet, says the infusion is diluted to 100 to 250 mL and given daily over 15 to 60 minutes for at least 10 to 20 days (Florek et al., 2025). No study has set a dose for use outside a trial, and we don’t give dosing advice.

Is Cerebrolysin made from pig brain?

Yes. It is made from enzymatically digested pig brain protein (Gevaert et al., 2015).

Sources

  1. Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026. PubMed 37818733
  2. Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-6. PubMed 22282884
  3. Muresanu DF, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-9. PubMed 26564102
  4. Guekht A, et al. Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurol Sci. 2017;38(10):1761-1769. PubMed 28707130
  5. Bornstein NM, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. PubMed 29248999
  6. Strilciuc S, et al. Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials. Pharmaceuticals (Basel). 2021;14(12):1297. PubMed 34959697
  7. Patel PN, et al. Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials. Cureus. 2025;17(8):e91054. PubMed 41018475
  8. Vosko MR, et al. C-REGS2-A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke. Int J Stroke. 2025;20(9):1060-1070. PubMed 40851188
  9. Khasanova DR, et al. Cerebrolysin as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study. BMC Neurol. 2023;23(1):121. PubMed 36973684
  10. Staszewski J, et al. Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. Transl Stroke Res. 2025;16(6):1931-1946. PubMed 40325343
  11. Woo PYM, et al. Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage. BMC Neurol. 2020;20(1):401. PubMed 33143640
  12. Homberg V, et al. Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke. 2025;56(4):937-947. PubMed 39957612
  13. Poon W, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41(2):281-293. PubMed 31494820
  14. Muresanu DF, et al. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci. 2020;41(5):1171-1181. PubMed 31897941
  15. Vester JC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(11):4531-4541. PubMed 33620612
  16. Cui S, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11):CD008900. PubMed 31710397
  17. Guekht AB, et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011;20(4):310-8. PubMed 20656516
  18. Gauthier S, et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-47. PubMed 25832905
  19. Alvarez XA, et al. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res. 2011;8(5):583-91. PubMed 21679156
  20. Xiao S, et al. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. Aust N Z J Psychiatry. 2012;46(2):153-60. PubMed 22311531
  21. Florek S, et al. Is Cerebrolysin Useful in Psychiatry Disorders?. Biomedicines. 2025;13(7):1661. PubMed 40722733
  22. Funke M, et al. Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. J Neural Transm Suppl. 1998;53:385-98. PubMed 9700674
  23. Alvarez XA, et al. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J Neural Transm Suppl. 2000;59:315-28. PubMed 10961443
  24. Gevaert B, et al. Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry. Drug Test Anal. 2015;7(9):835-42. PubMed 26017115
  25. Yang B, et al. Optimized approach for active peptides identification in Cerebrolysin by nanoLC-MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1225:123755. PubMed 37220681
  26. Seidl LF, et al. Comparing the biological activity and composition of Cerebrolysin with other peptide preparations. J Med Life. 2024;17(1):24-27. PubMed 38737662
  27. Zhang L, et al. Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke. Stroke. 2013;44(7):1965-72. PubMed 23696546
  28. Trimmel H, et al. Life-Threatening Anaphylaxis due to Cerebrolysin®. Case Rep Neurol Med. 2024;2024:2332908. PubMed 39055722
  29. Sadigh-Eteghad S, et al. Intranasal cerebrolysin improves cognitive function and structural synaptic plasticity in photothrombotic mouse model of medial prefrontal cortex ischemia. Neuropeptides. 2018;71:61-69. PubMed 30054019
  30. EVER Neuro Pharma. About Cerebrolysin: safety and prescribing information (Austrian summary of product characteristics). Maker’s page
  31. EVER Neuro Pharma. Cerebrolysin FAQs. Maker’s page
  32. EVER Neuro Pharma. Cerebrolysin home page, notice to U.S. visitors. Maker’s page
  33. ClinicalTrials.gov. Cerebrolysin studies, searched November 12, 2026, including NCT00868283, NCT00947531, NCT00911807, NCT01606111, NCT02541227 and NCT03480698. Search
  34. U.S. Department of Justice, Eastern District of Kentucky. Compounding pharmacy and its owner plead guilty to unlawful distribution of prescription drugs. October 29, 2020. Press release
  35. U.S. Department of Justice, Eastern District of Kentucky. Compounding pharmacy and its owner sentenced for unlawful distribution of prescription drugs. February 24, 2021. Press release
  36. U.S. Food and Drug Administration. Drugs@FDA data via openFDA, searched November 12, 2026: no Cerebrolysin product or label. openFDA search, no match
  37. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  38. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
  39. World Anti-Doping Agency. 2026 Prohibited List. WADA document
  40. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  41. U.S. Food and Drug Administration. Global Substance Registration System: CEREBROLYSIN (UNII 37KZM6S21G). GSRS

Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.